Mitsubishi UFJ Asset Management Co. Ltd. Takes $1.47 Million Position in The Chemours Company $CC

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of The Chemours Company (NYSE:CC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 71,468 shares of the specialty chemicals company’s stock, valued at approximately $1,467,000.

Several other institutional investors have also modified their holdings of the business. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Chemours in the 1st quarter valued at approximately $3,745,000. Old West Investment Management LLC acquired a new stake in shares of Chemours during the second quarter worth approximately $7,152,000. Versor Investments LP acquired a new stake in shares of Chemours during the fourth quarter worth approximately $314,000. Penn Capital Management Company LLC increased its stake in shares of Chemours by 113.0% in the fourth quarter. Penn Capital Management Company LLC now owns 1,386,819 shares of the specialty chemicals company’s stock worth $16,366,000 after buying an additional 735,668 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Chemours by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 17,920,868 shares of the specialty chemicals company’s stock valued at $211,287,000 after acquiring an additional 490,778 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Insider Buying and Selling

In related news, CFO Shane Hostetter bought 3,350 shares of the stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $14.94 per share, with a total value of $50,049.00. Following the completion of the acquisition, the chief financial officer owned 102,698 shares of the company’s stock, valued at $1,534,308.12. This trade represents a 3.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. This trade represents a 3.42% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 8,663 shares of company stock worth $130,601 over the last quarter. 0.85% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on CC. Weiss Ratings downgraded shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. dropped their target price on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. The Goldman Sachs Group restated a “neutral” rating and issued a $17.00 target price on shares of Chemours in a research note on Thursday, August 13th. BMO Capital Markets decreased their price target on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada decreased their price target on Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.10.

Chemours Stock Performance

Shares of CC opened at $15.96 on Friday. The stock has a market capitalization of $2.40 billion, a PE ratio of -8.36 and a beta of 1.43. The business’s fifty day moving average price is $18.01 and its 200 day moving average price is $20.01. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The Chemours Company has a 12-month low of $10.44 and a 12-month high of $28.67.

Chemours (NYSE:CC) last released its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.54) EPS. Equities research analysts forecast that The Chemours Company will post 0.87 EPS for the current year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be given a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, August 14th. Chemours’s dividend payout ratio is currently -18.32%.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $2.05 from $1.95 and increased Q4 2027 EPS to $0.61 from $0.53, suggesting improved profitability may emerge beyond 2026.
• Positive Sentiment: The firm also lifted estimates for Q1 2027 EPS to $0.40 from $0.39, Q3 2027 EPS to $0.58 from $0.56, Q1 2028 EPS to $0.56 from $0.55, and Q2 2028 EPS to $0.65 from $0.61.
• Neutral Sentiment: The revisions indicate a potentially stronger longer-term earnings trajectory, but they are offset by weaker expectations for the company’s immediate results. Zacks’ current full-year EPS consensus is approximately $0.87.
• Negative Sentiment: Zacks cut its FY2026 EPS forecast to $0.83 from $0.90 and reduced Q4 2026 EPS to $0.11 from $0.12, signaling pressure on near-term earnings.
• Negative Sentiment: The largest revision was a reduction in Q3 2026 EPS to $0.25 from $0.41. That forecast implies a substantial decline from the previous estimate and could weigh on investor sentiment.
• Negative Sentiment: FY2028 EPS was also lowered to $2.31 from $2.38, indicating that longer-term optimism is not broad-based. Chemours recently missed quarterly revenue and EPS expectations, adding to concerns about operating momentum.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.